Because of its immersion in the life sciences industry, IPS-Integrated Project Services, LLC (IPS) – a Blue Bell-based provider of engineering, procurement, construction management, and validation (EPCMV) services – is positively impacting the lives of so many people throughout the world at a time when it’s needed the most.

With a global staff of nearly 1,400 employees and a reach that spans ten countries in four continents, IPS is a leader in developing innovative solutions for technically complex pharmaceutical development and manufacturing facilities and is one of the fastest-growing companies in its space.

Having been founded in 1989, IPS has evolved from an execution-based company to a knowledge-based one that has attracted subject matter experts (SMEs) who do not just design and construct facilities but solve a client’s problem. IPS’ extensive roster of industry-recognized SMEs – many of whom have owner-side operating experience – possess deep global regulatory and best-in-class technical expertise.

“IPS is being asked by many companies, large and small, to help them in their pursuit of developing a vaccine or a therapeutic drug for COVID-19,” said CEO Dave Goswami. “This is not just in the United States; we are helping companies and organizations all over the world. This pandemic reminds us that the work we do really matters.”

The company recently celebrated its 31st anniversary. At a time when many companies are laying off workers, IPS is not only retaining its employees; it is hiring new ones.

“As we continue to grow,” said Goswami, “we do not lose sight of what has brought us to today: listening to the needs and challenges of our clients and providing integrated project and business solutions that help them create and manufacture life-impacting products.”

With technical expertise spanning research and development to large-scale production, IPS specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve operations.

IPS recently received three Facility of the Year Awards (FOYA) from The International Society for Pharmaceutical Engineering (ISPE), including United Therapeutics Corporation for the Social Impact Category. The FOYA recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery.

IPS provided inceptioneering™, design, and engineering services for United Therapeutics’ Dinutuximab-Dedicated Oncology Medical & Analytical Laboratory (DDOMAL) in Silver Spring, MD. The judging team was “especially impressed by the sheer number of challenges this project had to overcome, while never losing focus on why they were doing this work. The project also took the time to consider the impacts to the community both during and after construction.”

“We are so thankful to have been involved in the DDOMAL project,” said Tom J. Piombino, Vice President/Process Architect for IPS. “We were given a chance to help kids with cancer, to think completely outside the box (literally), and to collaborate with a great team of people in delivering something profound.”

Throughout this pandemic, IPS is continuing to work with local and global companies like UT to get research and development and clinical trials up and running, construct manufacturing facilities, and update existing sites to prevent drug shortages and help find a solution to our current global crisis.

Click here to learn more about IPS-Integrated Project Services, LLC.

[lp-contribute]